A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Completed · Phase 3 · NCT03926130
Conditions: Crohn's Disease
At a glance
- Research payments reported, 2025
- $117,142
- U.S. investigators named
- 20
- Sites paid
- 13
- Planned or actual enrollment
- 1,158
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Mirikizumab (drug), Mirikizumab (drug), Ustekinumab (drug), Ustekinumab (drug), Placebo (drug), Placebo (drug)
- Dates
- Started 2019-07-23; completion 2023-10-02
- Results posted
- Yes
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
From ClinicalTrials.gov, last updated 2024-12-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $117,142 in research payments for this study in 2025 (20 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Paul B. Lamb, MD Gastroenterology · Dothan, AL
- Kirk Russ Gastroenterology · Birmingham, AL
- Calin S. Arimie, MD Gastroenterology · West Hills, CA
- Jatinder S. Pruthi, M.D. Gastroenterology · Lancaster, CA
- Hendry J. Perez Pascual, M.D Family Medicine · Miami Gardens, FL
- Aniq Shaikh, MD Gastroenterology · Orlando, FL
- Julia J. Liu, MD Gastroenterology · Atlanta, GA
- Aasim M. Sheikh, MD Gastroenterology · Marietta, GA
- Todd A. Williams, M.D. Gastroenterology · Idaho Falls, ID
- David C. Chua, MD Gastroenterology · Oakbrook Terrace, IL
- Christopher R. Bartalos, DO Gastroenterology · Lees Summit, MO
- Kwadwo Agyei-gyamfi, M.D. Gastroenterology · Lumberton, NC
- Blanche Fung Liu, M.D. Specialist · New Hyde Park, NY
- Jeffry A. Katz, MD Gastroenterology · Cleveland, OH
- Sayed M. Yossef, M.D. Gastroenterology · Poland, OH
- Glenn S. Freed, DO Gastroenterology · Pottsville, PA
- Julien Fahed, M.D. Gastroenterology · Houston, TX
- Chad M. Gonzales, M.D. Gastroenterology · Ogden, UT
- Peder J. Pedersen, M.D. Gastroenterology · Salt Lake City, UT
- William H. Holderman, M.D. Gastroenterology · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Care Access Research LLC $46,842
- New York University $17,059
- Morehouse School of Medicine Inc $15,350
- Grand Teton Research Group PLLC $9,673
- Gastrointesinal Specialists of Georgia PC $5,640
- University of Alabama Hospital, AL $4,500
- Washington Gastroenterology PLLC $3,513
- Bvl Clinical Research $3,250
- Om Research LLC $3,000
- Calin Arimie MD $2,500
- Uh Cleveland Medical Center, OH $2,500
- Ezy Medical Research Co $2,315
- Digestive Health Specialists $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.